Drug Trial Radar · NCT00334282
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Feb 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
435
Actual
Start
Apr 2006
Primary completion
May 2008
Study completion Dec 2014
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 7, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC). Approximately 350-400 eligible patients will be stratified and randomized in a 2:1 ratio to receive either 800 mg pazopanib once daily or matching placebo. The study treatment will continue until patients experience disease progression, unacceptable toxicity or death. Primary objective of the study is to evaluate and compare the two treatment arms for progression-free survival. Principal secondary objective is to evaluate and compare the two treatment arms with respect to overall survival. Other objectives are overall response rate \[complete response (CR) + partial response (PR)\], rate of CR + PR + 6 months stable disease, and the incidence, severity and causality of adverse events and serious adverse events. Safety and efficacy assessments will be regularly performed on all patients. An Independent Data Monitoring Committee will be established to monitor safety during the course of the study and to evaluate interim efficacy data on overall survival.
Conditions
- Carcinoma, Renal Cell
Interventions
PazopanibDrug
Oral pazopanib tablet 800 mg once daily continuously
placeboDrug
matching placebo (800 mg tablet) once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free SurvivalTime frame: Randomization until progression (up to 2 years)
Locations
99 sites in 25 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Quilmes, Argentina
GSK Investigational Site
San Miguel de Tucumán, Argentina
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
St Leonards, New South Wales, Australia
GSK Investigational Site
Waratah, New South Wales, Australia
GSK Investigational Site
Hobart, Tasmania, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Wodonga, Victoria, Australia
GSK Investigational Site
Salzburg, Austria
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Jaú, São Paulo, Brazil
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Viña del Mar, Valparaiso, Chile
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Brno, Czechia
GSK Investigational Site
Chomutov, Czechia
GSK Investigational Site
Ostrava - Poruba, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tartu, Estonia
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Pátrai, Greece
GSK Investigational Site
Thessaloniki, Greece
GSK Investigational Site
Hong Kong, Hong Kong
GSK Investigational Site
Kowloon, Hong Kong
GSK Investigational Site
Tuen Mun, New Territories, Hong Kong
GSK Investigational Site
Bangalore, India
GSK Investigational Site
Hyderabad, India
GSK Investigational Site
Mumbai, India
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.